A2ti-2
|
A651937-25mg
|
≥99% |
482646-13-9 |
25mg
|
¥ 11000.9
|
期货,请咨询 |
阿拉丁 |
A2ti-2
|
A651937-10mg
|
≥99% |
482646-13-9 |
10mg
|
¥ 5800.9
|
期货,请咨询 |
阿拉丁 |
A2ti-2
|
A651937-100mg
|
≥99% |
482646-13-9 |
100mg
|
¥ 25000.9
|
期货,请咨询 |
阿拉丁 |
AGN-195183
|
A651924-5mg
|
≥99% |
367273-07-2 |
5mg
|
¥ 3000.9
|
期货,请咨询 |
阿拉丁 |
AGN-195183
|
A651924-50mg
|
≥99% |
367273-07-2 |
50mg
|
¥ 13500.9
|
期货,请咨询 |
阿拉丁 |
AGN-195183
|
A651924-25mg
|
≥99% |
367273-07-2 |
25mg
|
¥ 9000.9
|
期货,请咨询 |
阿拉丁 |
AGN-195183
|
A651924-10mg
|
≥99% |
367273-07-2 |
10mg
|
¥ 4500.9
|
期货,请咨询 |
阿拉丁 |
AM-2099
|
A651904-5mg
|
≥98% |
1443373-17-8 |
5mg
|
¥ 900.9
|
期货,请咨询 |
阿拉丁 |
AM-2099
|
A651904-50mg
|
≥98% |
1443373-17-8 |
50mg
|
¥ 4000.9
|
期货,请咨询 |
阿拉丁 |
AM-2099
|
A651904-10mg
|
≥98% |
1443373-17-8 |
10mg
|
¥ 1500.9
|
期货,请咨询 |
阿拉丁 |
AM-2099
|
A651904-100mg
|
≥98% |
1443373-17-8 |
100mg
|
¥ 6500.9
|
期货,请咨询 |
阿拉丁 |
(Sar1)-Angiotensin II
|
A651887-5mg
|
≥99% |
51833-69-3 |
5mg
|
¥ 3500.9
|
期货,请咨询 |
阿拉丁 |
(Sar1)-Angiotensin II
|
A651887-1mg
|
≥99% |
51833-69-3 |
1mg
|
¥ 1600.9
|
期货,请咨询 |
阿拉丁 |
(Sar1)-Angiotensin II
|
A651887-10mg
|
≥99% |
51833-69-3 |
10mg
|
¥ 5800.9
|
期货,请咨询 |
阿拉丁 |
ARN-21934
|
A651864-5mg
|
≥98% |
2230854-93-8 |
5mg
|
¥ 3500.9
|
期货,请咨询 |
阿拉丁 |
ARN-21934
|
A651864-50mg
|
≥98% |
2230854-93-8 |
50mg
|
¥ 17000.9
|
期货,请咨询 |
阿拉丁 |
ARN-21934
|
A651864-25mg
|
≥98% |
2230854-93-8 |
25mg
|
¥ 11000.9
|
期货,请咨询 |
阿拉丁 |
ARN-21934
|
A651864-10mg
|
≥98% |
2230854-93-8 |
10mg
|
¥ 5800.9
|
期货,请咨询 |
阿拉丁 |
ARN-21934
|
A651864-100mg
|
≥98% |
2230854-93-8 |
100mg
|
¥ 25000.9
|
期货,请咨询 |
阿拉丁 |
Abemaciclib metabolite M20
|
A651853-5mg
|
≥96% |
2138499-06-4 |
5mg
|
¥ 3500.9
|
期货,请咨询 |
阿拉丁 |
Abemaciclib metabolite M20
|
A651853-50mg
|
≥96% |
2138499-06-4 |
50mg
|
¥ 16500.9
|
期货,请咨询 |
阿拉丁 |
Abemaciclib metabolite M20
|
A651853-25mg
|
≥96% |
2138499-06-4 |
25mg
|
¥ 9900.9
|
期货,请咨询 |
阿拉丁 |
Abemaciclib metabolite M20
|
A651853-1mg
|
≥96% |
2138499-06-4 |
1mg
|
¥ 1800.9
|
期货,请咨询 |
阿拉丁 |
Abemaciclib metabolite M20
|
A651853-10mg
|
≥96% |
2138499-06-4 |
10mg
|
¥ 5500.9
|
期货,请咨询 |
阿拉丁 |